Literature DB >> 27856510

Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.

Rick Proschmann1, Christoph Baldow1, Tino Rothe1, Meinolf Suttorp2, Christian Thiede3, Josephine T Tauer2, Martin C Müller4, Andreas Hochhaus5, Ingo Roeder1,6, Ingmar Glauche7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27856510      PMCID： PMC5286951          DOI： 10.3324/haematol.2016.154138

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.

Authors:  Fiorina Giona; Stefania Mariani; Lucio Gnessi; Maria Luisa Moleti; Massimiliano Rea; Annalisa De Vellis; Deborah Marzella; Anna Maria Testi; Robin Foà
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

2.  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Authors:  Benjamin Hanfstein; Michael Lauseker; Rüdiger Hehlmann; Susanne Saussele; Philipp Erben; Christian Dietz; Alice Fabarius; Ulrike Proetel; Susanne Schnittger; Claudia Haferlach; Stefan W Krause; Jörg Schubert; Hermann Einsele; Mathias Hänel; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Markus Pfirrmann; Joerg Hasford; Wolf-Karsten Hofmann; Andreas Hochhaus; Martin C Müller
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

3.  Imatinib has adverse effect on growth in children with chronic myeloid leukemia.

Authors:  Deepak Bansal; Upender Shava; Neelam Varma; Amita Trehan; R K Marwaha
Journal:  Pediatr Blood Cancer       Date:  2011-11-02       Impact factor: 3.167

4.  BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.

Authors:  Andrew M Stein; Dean Bottino; Vijay Modur; Susan Branford; Jaspal Kaeda; John M Goldman; Timothy P Hughes; Jerald P Radich; Andreas Hochhaus
Journal:  Clin Cancer Res       Date:  2011-09-08       Impact factor: 12.531

Review 5.  Dysregulation of bone remodeling by imatinib mesylate.

Authors:  Kate Vandyke; Stephen Fitter; Andrea L Dewar; Timothy P Hughes; Andrew C W Zannettino
Journal:  Blood       Date:  2009-11-04       Impact factor: 22.113

6.  Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.

Authors:  Josu de la Fuente; André Baruchel; Andrea Biondi; Eveline de Bont; Marie-Françoise Dresse; Meinolf Suttorp; Frédéric Millot
Journal:  Br J Haematol       Date:  2014-06-30       Impact factor: 6.998

7.  Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.

Authors:  Andrew M Stein; Giovanni Martinelli; Timothy P Hughes; Martin C Müller; Lan Beppu; Enrico Gottardi; Susan Branford; Simona Soverini; Richard C Woodman; Andreas Hochhaus; Dong-Wook Kim; Giuseppe Saglio; Jerald P Radich
Journal:  BMC Cancer       Date:  2013-04-02       Impact factor: 4.430

Review 8.  Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

Authors:  N C P Cross; H E White; D Colomer; H Ehrencrona; L Foroni; E Gottardi; T Lange; T Lion; K Machova Polakova; S Dulucq; G Martinelli; E Oppliger Leibundgut; N Pallisgaard; G Barbany; T Sacha; R Talmaci; B Izzo; G Saglio; F Pane; M C Müller; A Hochhaus
Journal:  Leukemia       Date:  2015-02-05       Impact factor: 11.528

9.  Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Jianqin Shan; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; William Wierda; Susan O'Brien; Jorge Cortes
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

10.  Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

Authors:  Lida Kalmanti; Susanne Saussele; Michael Lauseker; Ulrike Proetel; Martin C Müller; Benjamin Hanfstein; Annette Schreiber; Alice Fabarius; Markus Pfirrmann; Susanne Schnittger; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Stefan W Krause; Dominik Heim; Christoph Nerl; Dieter K Hossfeld; Hans-Jochem Kolb; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann
Journal:  Ann Hematol       Date:  2013-10-27       Impact factor: 3.673
View more
  1 in total

Review 1.  Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.

Authors:  Monika Sparber-Sauer; Daniel Orbach; Fariba Navid; Simone Hettmer; Stephen Skapek; Nadège Corradini; Michela Casanova; Aaron Weiss; Matthias Schwab; Andrea Ferrari
Journal:  Br J Cancer       Date:  2021-03-15       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.